- Publishing of Findings in Recent Pre-Clinical Study for LIXTE’s Proprietary Compound, LB-100, in New Field of Cancer Biology, “Activation Lethality”
- Presentation at
MedInvest Biotech and Pharma Investor Conference - Co-Sponsorship/Presentation of Workshop at Harvard University’s
Dana Farber Cancer Institute
“LIXTE continues to make progress with its proprietary compound, LB-100, in ongoing clinical trials for lung, ovarian and sarcoma cancers,” said
- Pre-clinical studies in a new field of cancer biology -- activation lethality -- have shown that LB-100 can force cancer cells to give up their cancer-causing properties. The findings open a potentially new treatment strategy in addition to LIXTE’s current three ongoing clinical trials.
René Bernards , Ph.D., a leader in the field of molecular carcinogenesis and Senior Staff Scientist at the Netherlands Cancer Institute, presented the new pre-clinical data at theJoint Conference of European and American Associations for Cancer Research inDublin, Ireland . The paper, “Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy,” was posted in the online medical journal Cancer Discovery onApril 30, 2024 .Dr. Bernards is a member of LIXTE’s Board of Directors. Bas van der Baan , LIXTE’s President and Chief Executive Officer, presented at theMedInvest Biotech and Pharma Investor Conference onApril 3, 2024 inNew York City . The two-day event featured presentations from more than 40 companies, developing and commercializing technologies across a broad spectrum of indications, including oncology. The conference also featured talks from key industry opinion leaders, investor panel discussions, and conversations with theNational Cancer Institute on patenting, facilitating collaborations, licensing and technology analysis and marketing.- LIXTE co-sponsored an international scientific workshop on “Therapeutic Over-Activation in Cancer” at Harvard University’s
Dana Farber Cancer Institute inBoston, Massachusetts onMay 9 and 10, 2024. The workshop brought together leading experts from the pharmaceutical industry and academia who discussed a radically different approach to cancer therapy that is being spearheaded by LIXTE’s outsourced research team at theNetherlands Cancer Institute .
LIXTE has clinical trials underway at the
Click here for a brief video overview by LIXTE’s Chief Executive Officer.
Filing of Quarterly Report on Form 10-Q for the three months ended
Additional information with respect to LIXTE’s business, clinical trials and financial condition is contained in the Company’s Quarterly Report on Form 10-Q for the three months ended
About
Forward-Looking Statement Disclaimer
This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future activities, including the continuing development of proprietary compounds, the planning, funding, coordination and potential results of clinical trials, the patent and legal costs to protect and maintain the Company's intellectual property worldwide, and the Company’s ability to obtain and maintain compliance with Nasdaq’s continued listing requirements, are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology.
The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash resources, research results, competition from other similar businesses, and market and general economic factors.
Readers are urged to read the risk factors set forth in the Company’s filings with the
For more information about LIXTE, Contact:
info@lixte.com
General Phone: (631) 830-7092
Investor Phone: (888) 289-5533
or
pwinvestor@pondel.com
Source:
2024 GlobeNewswire, Inc., source